Wednesday, August 10, 2016

BRIEF-VTV Therapeutics announces positive initial topline results from Phase 2b study of Glucokinase Activator TTP399

* VTV Therapeutics announces positive initial topline

results from phase 2b study of glucokinase activator ttp399 in

type 2 diabetes

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)